Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$179.10 +1.9%	$165.82	$111.09 ▼ $183.00	$10.75B	0.37	496,069 shs	377,009 shs
JAZZ Jazz Pharmaceuticals	$108.11 +1.3%	$108.34	$95.49 ▼ $148.06	$6.46B	0.33	824,666 shs	454,555 shs
MDGL Madrigal Pharmaceuticals	$284.98 +0.7%	$293.01	$200.63 ▼ $377.46	$6.28B	-1.08	359,513 shs	298,118 shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.63%	-1.09%	+8.51%	+9.15%	+37.49%
JAZZ Jazz Pharmaceuticals	-0.70%	-2.63%	-1.21%	-21.06%	-1.12%
MDGL Madrigal Pharmaceuticals	-0.96%	-0.73%	+5.77%	-17.57%	+1.64%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	2.6367 of 5 stars	3.5	3.0	0.0	0.0	2.2	1.7	0.6
JAZZ Jazz Pharmaceuticals	4.9098 of 5 stars	4.5	2.0	0.0	4.0	2.8	3.3	2.5
MDGL Madrigal Pharmaceuticals	4.1287 of 5 stars	3.4	1.0	0.0	4.6	1.9	3.3	0.6
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	23.21% Upside
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	70.20% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	47.60% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRVB, ASND, JAZZ, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/9/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$201.00 ➝ $216.00
6/3/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$196.00 ➝ $201.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/12/2025	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$393.54M	27.82	N/A	N/A	($1.88) per share	-95.27
JAZZ Jazz Pharmaceuticals	$4.07B	1.61	$30.71 per share	3.52	$67.72 per share	1.60
MDGL Madrigal Pharmaceuticals	$180.13M	35.12	N/A	N/A	$34.59 per share	8.24
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	746.25	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	14.41	5.78	4.61	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A

Latest PRVB, ASND, JAZZ, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.04	0.71
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
PRVB Provention Bio	0.19	1.93	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
JAZZ Jazz Pharmaceuticals	89.14%
MDGL Madrigal Pharmaceuticals	98.50%
PRVB Provention Bio	37.39%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
JAZZ Jazz Pharmaceuticals	4.30%
MDGL Madrigal Pharmaceuticals	21.50%
PRVB Provention Bio	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable

PRVB, ASND, JAZZ, and MDGL Headlines

Recent News About These Companies

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

March 9, 2025 | pharmaphorum.com

FDA rejects Provention's type 1 diabetes drug teplizumab

November 19, 2024 | pharmaphorum.com

Kimber Creek Ford

August 2, 2024 | cars.com

Ann Tricklebank Biography & Movies

May 25, 2024 | tribute.ca

VOA News

May 23, 2024 | voanews.com

Topic - Cumberland Valley School District

May 5, 2024 | washingtontimes.com

Macrogenics Inc MGNX

December 29, 2023 | morningstar.com

And for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetes

November 13, 2023 | medpagetoday.com

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

October 24, 2023 | nejm.org

FDA sets August decision date for Provention's type 1 diabetes drug

July 23, 2023 | pharmaphorum.com

Larry Pine Biography & Movies

June 27, 2023 | tribute.ca

Sanofi/Provention: innovative diabetes drug is a good fit

May 1, 2023 | finance.yahoo.com

Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%

April 29, 2023 | finance.yahoo.com

Sanofi completes Provention Bio acquisition

April 28, 2023 | seekingalpha.com

Sanofi concludes acquisition of Provention Bio

April 28, 2023 | medicaldialogues.in

Sanofi completes acquisition of Provention Bio, Inc.

April 28, 2023 | pharmiweb.com

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

April 27, 2023 | finance.yahoo.com

Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 27, 2023 | finanznachrichten.de

Provention Bio gains after HSR waiting period for Sanofi deal expired

April 26, 2023 | seekingalpha.com

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 26, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRVB, ASND, JAZZ, and MDGL Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$179.10 +3.32 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$178.92 -0.17 (-0.10%)

As of 06:32 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.11 +1.35 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$107.50 -0.61 (-0.56%)

As of 06:38 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Madrigal Pharmaceuticals NASDAQ:MDGL

$284.98 +1.99 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$285.99 +1.01 (+0.36%)

As of 07:56 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time